BioCentury | Jan 16, 2021
Product Development

Zymeworks showcases >45% confirmed ORRs for anti-HER2 bispecific in biliary, gastroesophageal cancers

Phase I data Zymeworks presented Friday for its bispecific anti-HER2 mAb back its ongoing and pending pivotal trials in biliary tract and gastroesophageal cancers, respectively. In an oral presentation at the American Society of Clinical Oncology...
BioCentury | Jan 15, 2021
Finance

A maturing mid-cap sector could keep funds flowing into biotech

While it’s too early to say whether 2020’s record year of fund-raising constitutes a “new normal,” there’s consensus among buysiders and bankers that a cheap money environment will continue in 2021 as...
BioCentury | Jan 15, 2021
Regulation

Jan. 14 Quick Takes: Lexicon rises on NDA timeline for heart failure program; plus: FDA COVID reports and updates from BeiGene, Merck, Bayer

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) gained $4.13 (105%) to $8.05 Thursday after saying data from its Phase III SOLOIST and SCORED trials of sotagliflozin could support an NDA submission as early as this year to reduce...
BioCentury | Jan 13, 2021
Finance

IPO filing reveals details of Sana’s deep pipeline, aggregation of next-generation gene and cell therapy technologies

With its IPO filing Wednesday, well-funded start-up Sana has lifted the lid on a suite of technologies it has aggregated since 2018, giving it a pipeline of 11 cell and gene therapies. Its first INDs...
BioCentury | Jan 13, 2021
Regulation

Jan. 12 Quick Takes: U.S. releases all doses of mRNA vaccines; more Regeneron mAb under HHS deal, plus Black Diamond

Azar says all COVID vaccine doses releasedHHS Secretary Alex Azar said Tuesday on Good Morning America that every dose of Moderna COVID-19 Vaccine from Moderna Inc. (NASDAQ:MRNA) and Comirnaty from Pfizer Inc. (NYSE:PFE) and BioNTech...
BioCentury | Jan 12, 2021
Deals

bluebird’s split could yield two attractive M&A targets

bluebird’s decision to focus on rare diseases and spin out its cancer business by year-end could provide the focus both units need to execute on their pipelines and attract potential partners and buyers.  Nick Leschly,...
BioCentury | Jan 12, 2021
Finance

Diverse syndicate stands behind EQRx’s mission with $500M series B round

EQRx is planning to deliver on its promise to provide equivalent or better low-cost drugs ahead of schedule with a $500 million series B, with diverse investor interest reflecting a mission that has only...
BioCentury | Jan 12, 2021
Deals

Sanofi joins the myeloid checkpoint movement with Biond deal

Sanofi is staking claims in next-generation checkpoints through a new deal with Israeli biotech Biond around myeloid checkpoint target ILT2.  The deal with Biond Biologics Ltd., which gives the biotech $125 million up front and...
BioCentury | Jan 12, 2021
Product Development

OX40L pipeline: Data Byte

Kymab leads the pack among companies targeting OX40L for autoimmune disorders, while Moderna has the most advanced program against the target for cancer.  OX40L, the ligand for the OX40 receptor, is expressed on activated antigen-presenting...
BioCentury | Jan 12, 2021
Deals

Jan. 11 Quick Takes: Inmagene gains options to four Chi-Med immunology programs; plus Zai-Turning Point, Mirati-Resolution, GSK-Eligo, Biogen-Apple, Adaptive-AZ and more

Chi-Med, Inmagene partner on immunological indicationsHutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) granted Inmagene Biopharmaceuticals Co. Ltd. exclusive options to four immunological diseases programs for up to $95 million in development milestones, $135 million in commercial...
Items per page:
1 - 10 of 18882